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Statement of Translational Relevance
Cytotoxic chemotherapy has not been shown to improve outcomes for patients with advanced hepatocellular carcinoma (HCC). Recently sorafenib, a small molecule, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR), was shown to improve survival for these patients. These benefits appear to be variable, modest, and with some toxicities, thus highlighting there are still many unmet needs. An increased understanding of the pathogenesis of HCC suggests a role for the fibroblast growth factor (FGF) family. These data provide rationale for the current Phase II study evaluating brivanib, a first in class, oral, selective dual inhibitor of FGF and VEGF signaling in HCC. This study demonstrates the antitumor activity and tolerability of brivanib and supports the ongoing phase III program of brivanib in HCC. In addition, the current study incorporates the newly proposed modified RECIST criteria to assess antitumor activity in HCC. 
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide (1) and the third largest cause of cancer-related deaths (2) . HCC is unique in that it represents two diseases, primary liver dysfunction/cirrhosis and malignancy.
These two comorbid conditions create unique clinical challenges, particularly since agents with efficacy against malignant growth may worsen underlying cirrhosis, making it difficult to interpret composite end-points (3) . As HCC is a highly vascularized tumor, therapeutic concepts targeting key molecular pathways involved in tumor angiogenesis are of particular interest in targeting malignancy. Sorafenib, an inhibitor of vascular endothelial growth factor (VEGFR-2), c-Kit, and raf, has demonstrated activity and tolerability in advanced HCC (4, 5) .
Fibroblast growth factor-2 (FGF-2) is a potent angiogenic factor in HCC (6) (7) (8) (9) .
Upregulation of alternate proangiogenic signals, such as the FGF signaling pathway, may play a role in evasive resistance to VEGF-targeted antiangiogenic therapy (10) . Moreover, preclinical data suggest that while VEGF inhibitors reduce primary tumor growth, they also promote tumor invasiveness and metastasis in two mouse models with melanoma or pancreatic cancer (11) (12) (13) .
Brivanib, the first oral selective dual inhibitor of FGF and VEGF signaling, is formulated as an orally administered L-alanine ester prodrug, brivanib alaninate (14) . Brivanib has strong antiangiogenic effects, as well as potent direct effects, on tumor cells across a range of tumor types, including liver and colon (15- half-life of 12 hours and is administered once daily at a dose of 800 mg, with no reported differences in pharmacokinetics between Asian versus non-Asian races and patients with mild hepatic impairment versus patients with no hepatic impairment (18, 19) .
Here we present the results from a study of brivanib as first-line therapy in patients with unresectable, advanced HCC.
Study Design
This was originally a randomized study of brivanib versus doxorubicin in newly diagnosed HCC patients. At the time the protocol was initiated, no agent was proven to extend survival in HCC and doxorubicin was used as a comparator arm protocol and any amendments were approved by the independent ethics committee of each center and by the authorities in each relevant country.
Informed consent was obtained from each patient. Here we report results from Cohort A.
Patient eligibility
Patients with measurable, unresectable, locally advanced, or metastatic HCC, those with biopsy-proven HCC, or those who had clinical evidence of HCC (α-fetoprotein [AFP] levels ≥400 mg/L and standard imaging criteria)(21) and were serology positive for hepatitis B or C, with a Cancer of the Liver Italian Program (CLIP) score ≤3 and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and adequate hepatic function and renal function, were eligible for inclusion in the study (see online supplementary section A for full criteria).
Study Objectives
The primary objective was to estimate the 6-month progression-free survival rate.
Six-month progression-free survival rate was defined as the proportion of treated patients who had not progressed or expired prior to 6 months from the first dose.
Secondary objectives were median progression-free survival, tumor response rate, time to response, duration of response, disease control rate, time to 
Treatment and dose modifications
Brivanib was administered orally on a continuous daily schedule of 800 mg.
Patients continued treatment until first evidence of disease progression on imaging by mWHO criteria or earlier if unacceptable toxicity was observed.
Doses were reduced or delayed according to protocol-specified criteria or, for lower grade toxicities, if the investigator deemed dose reduction or delay was required in the interest of the patients' safety (online supplementary section C).
Tumor Assessments
Tumor response was assessed every 6 weeks using the modified World Health modified guidelines for HCC were introduced to measure reductions in viable tumor volume recognized as enhancing areas using dynamic imaging techniques.
All atypical intrahepatic and all extrahepatic lesions were assessed using conventional RECIST criteria as outlined in the recent proposed mRECIST for HCC publication (22) . 
Statistical Considerations
Sample size
A total of 50 treated subjects were required in the first line daily Cohort. This was the number of subjects needed so that the lower bound of the 95% confidence interval of the 6-month PFS rate would exclude 35% given the observed PFS rate at 6 month is 50% (see online supplementary section E for full details).
Analysis population
All analyses described in the manuscript included all subjects with no prior systemic therapy who were treated with 800 mg brivanib alaninate QD.
Statistical analysis (see online supplementary section E for full details)
The 6-month PFS rate for the First line QD Cohort, as per IRRC using the mWHO criteria, was the primary endpoint of this study. The 6-month PFS rate was defined as the number of subjects who had not progressed or died prior to 6
Research. months from the date of their first dose, divided by the number of subjects in the First line daily Cohort. An exact binomial 2-sided 95% confidence interval (CI) for the PFS rate was computed. The PFS rate at 6 months was also estimated using the Kaplan-Meier method and 95% CI was calculated using the Greenwood formula. For details see online supplementary section E. 
Results
Demographics
Six-month PFS rate
Using mWHO criteria, the 6-month progression-free survival rate calculated using the exact binomial method was 18.2% (95% CI, 9.1%-30.9%) as determined by IRRC assessment (primary end point; Table 2 ). The 6-month progression-free survival rate calculated using Kaplan-Meier estimates was 21.1% (95% CI, 9.6%-32.5%) as determined by IRRC assessment and 15.9% (95% CI, 5.8%-26.0%) as determined by investigator assessment.
Progression-free survival
Median progression-free survival was 2.7 (95% CI, 1.4-3.0) months by IRRC assessment (Fig. 3A) .
Tumor response
According to IRRC assessment with mWHO criteria, one patient had a complete response, three patients achieved a partial response and 24 had stable disease.
Two of these patients with stable disease had unconfirmed partial response (no repeat scans showing partial response). The disease control rate (partial response + stable disease ≥42 days) was 51% ( (3+24) /55, respectively).
Twenty patients had progressive disease and tumor responses were not assessable in 7.patients ( Fig. 1 ; Table 2 ). As assessed by the investigator, four patients achieved confirmed partial response and 24 had stable disease (of these one had an unconfirmed PR). The disease control rate (partial response + stable disease) was 51% ((4 + 24)/55 treated, respectively) by investigator. Fifteen patients had progressive disease. Tumor response was not assessable in 12 patients by investigator. Five patients had a baseline and at least 1 follow-up scan but no scan while on treatment. As a result, IRRC gave a best response for those 5 patients but were not assessable by the investigator.
Some patients achieved rapid objective responses while others showed slow improvement over time; the time to PR/unconfirmed PR ranged from 1.14 to 
Time to Progression
IRRC time to progression was 2.8 months (95% CI, 1.4-3.5) and investigator time to progression was 2.7 months (95% CI, 1.5-2.8).
HCC mRECIST vs mWHO Criteria
Using the proposed mRECIST criteria for HCC, the 6-month progression-free survival rate was 35.6% (95% CI: 21.0-49.4), median progression-free survival was 4.7 (95%CI, 2.8-5.7) months, and median time to progression was 5.4 months (95% CI, 2.8--) ( Table 2 ).
Upon mRECIST criteria for HCC, 26/55 patients had improved responses compared to mWHO criteria per IRRC. Among the 3 patients classified as partial response by mWHO, 1 was reclassified with complete response. Among the 24 patients classified as stable disease by mWHO, three patients were reclassified with complete response, six were reclassified with partial response (Table 2 ). In the original study protocol, treatment was terminated in patients who had an assessment of progressive disease. However,16 of 20 patients who were assessed as having a progressive disease using mWHO criteria actually had some evidence of tumor response by mRECIST and may have benefited from continued treatment. Of these, two were considered partial response and 14
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on were considered stable disease (including unconfirmed partial response and unconfirmed complete response). Using mRECIST, 2/55 patients had downgraded responses compared to mWHO (one stable disease was reclassified as progressive disease; one partial response became stable disease).
The disease control rate (complete response, partial response, and stable disease) using mRECIST was 78.2 % (95%CI 65.0%-88.2%) (43/55 treated)..
Patient examples are shown in Fig. 2 .
Overall survival and disease control status
Median overall survival was 10 (95% CI, 6.8-15.2) months ( Fig. 3B ; Table 2 ). 
AFP response
Seventy-six percent of patients had elevated AFP levels (greater than the upper limit of normal [ULN]) at baseline, 42% had an AFP >400 ng/mL. Among patients with an elevated (>ULN) AFP level at baseline (n = 41), 56% had a >50%
on reduction in AFP levels from baseline ( Fig. 3C ; online supplementary section Table A1 ).
Adverse events
Brivanib was generally well tolerated, with a manageable safety profile (Table   3A) . Eleven patients (21%) withdrew due to treatment-emergent AEs. Twentytwo patients (41%) had at least one dose reduction. Reasons for dose reductions were nonhematologic toxicities related to the study drug in 21 patients (95.5%).
Thirteen patients experienced drug-related serious AEs, which were grade 3/4 in 10 patients (Table 3B) . Twenty-six percent of patients had a diastolic blood pressure greater than 100 mm Hg and only 1.8% of patients had a diastolic blood pressure greater than 110 mm Hg during the treatment course. In addition, 25 patients (46%) had any-grade hypertension as a reported AE; grade 3/4 in six patients (11%). Grade 2 hypertension led to treatment discontinuation in one patient. Six patients (11%) experienced minor (grade 1/2, except for one grade 3 esophageal varices hemorrhage; none requiring blood transfusion) gastrointestinal bleeding events, including two minor anal bleedings (online supplementary section Table A2 ). Of note, only two patients (4%) experienced hand-foot syndrome, which was grade 1/2 in one patient and grade 3 in one patient, which were considered drug related. Three patients (5.5%) had grade 3 encephalopathy, which was considered drug-related in 1 patient. Of the 35 deaths that occurred (1 within 30 days of starting the trial and six within 30 days of the last dose), none were considered treatment related (30 patients died due to disease progression, five died due to other reasons). Eight patients (14.5%) had grade 3/4 hyponatremia; however, some patients may have entered the study with up to grade 3 hyponatremia; see online supplementary section D).
Subsequent therapy
No-one continued brivanib beyond progression; 25/55 (45.5%) subjects received subsequent therapy and 30/55 (54.5%) did not receive any subsequent therapy.
No patients received maintenance therapy with brivanib. 18/55 (32.7%) subjects received at least one targeted therapy (antiangiogenic agents, monoclonal antibodies, tyrosine kinase inhibitors, or other targeted therapies) as subsequent therapy, including 16 patients who received sorafenib.
Discussion
Results from this phase II study are preliminary evidence that brivanib as first-line therapy has antitumor activity and a manageable safety profile in advanced HCC in a predominantly Asian population with a high incidence of hepatitis B. This study did not reach the planned primary end point with a 6-month PFS of 18.2%, and median progression-free survival was 2.7 months. However, median overall survival was 10 months, which is an encouraging finding for this advanced-stage population that had a high incidence of extrahepatic disease and prior local treatment, together with brivanib's manageable safety profile.
The observed PFS and 6-month PFS was lower than expected. However, these results must be interpreted in the context of recent study results and changes to were originally assessed as PD via mWHO on their first scan were taken off study and then stopped brivanib when in reality they may have been having some treatment benefit, as shown by the proposed mRECIST criteria for HCC assessments. Using the proposed mRECIST for HCC, more responses were observed-including five CRs-substantially increasing the disease control rate.
In addition, median time to progression almost doubled with mRECIST. The proposed mRECIST for HCC criteria therefore merit further assessment in randomized Phase 3 studies and validation as a surrogate for long-term outcomes.
Brivanib as a first-line systemic treatment for advanced HCC demonstrated a median overall survival of 10 months, which is similar to the overall survival rate in studies of sorafenib as first-line therapy (4, 5) despite the fact that more than two-thirds of patients were enrolled in Asia in the brivanib study. In contrast, the phase III study of sorafenib in Asian patients reported an overall survival of 6.5 months (24) . Experts believe that the lower overall survival in the Asian versus non-Asian sorafenib study population was due to the degree of pretreatment, the severity of the underlying disease, and the tumor burden (24) . Additional differences in study design between the current study and the sorafenib studies, notably the SHARP study, make comparisons of overall survival difficult. For example, brivanib treatment was stopped in the current study in the case of progression when mWHO criteria were applied, whereas in the SHARP study mWHO criteria were used and sorafenib treatment was stopped in the case of Responses and major AFP reductions in the current study also demonstrate encouraging signs of biologic activity in HCC patients. Until recently, the role of monitoring AFP response in HCC had not been rigorously evaluated. However, two recent retrospective analyses of AFP response in HCC patients undergoing systemic chemotherapy (26) or locoregional therapy (27) reported that achievement of an AFP response is an independent prognostic factor in determining survival (26, 27) . In our study, more than half of patients with an elevated AFP (>ULN) level at baseline had a greater than 50% reduction in AFP levels from baseline following brivanib treatment. 
Grade 3/4 AEs included fatigue in 16.4% of patients and hypertension in 10.9% of patients. The incidence of all-grade hand-foot syndrome was 3.6% in the current study compared with 9% to 82% of HCC patients treated with sorafenib (4, 5, 10, 24, (28) (29) (30) (31) (32) , which led to dose reductions in 5% of patients in the SHARP study and 11.4% of patients in the sorafenib Asian Study (5, 24) . Despite brivanib's antiangiogenic properties, there were no serious AEs usually associated with antiangiogenic agents, and its use was not associated with an unusual incidence of gastrointestinal hemorrhage, particularly of variceal origin as seen with bevacizumab (33). 
